Burton James R, Everson Gregory T
Department of Medicine, Division of Gastroenterology and Hepatology, University of Colorado, Denver, Aurora, CO 80045, USA.
Clin Liver Dis. 2009 Aug;13(3):453-65. doi: 10.1016/j.cld.2009.05.001.
Chronic hepatitis C virus (HCV) infection affects approximately 4 million persons and is the major indication for liver transplantation in the United States. The current standard for treatment of HCV is pegylated interferon in combination with ribavirin. Despite significant advances in treatment, only approximately 50% of patients of treated patients clear HCV infection. Polymerase inhibitors, given their potent antiviral effects, represent a major contribution to the future of HCV treatment. Whether these new drugs will have a role in the treatment of the difficult patient (non-responders, those co-infected with HIV, decompensated liver disease and liver transplant recipients) remains to be determined.
慢性丙型肝炎病毒（HCV）感染影响着约400万人，并且是美国肝移植的主要指征。目前HCV的治疗标准是聚乙二醇化干扰素联合利巴韦林。尽管治疗取得了显著进展，但接受治疗的患者中只有约50%能清除HCV感染。聚合酶抑制剂因其强大的抗病毒作用，对HCV治疗的未来有着重大贡献。这些新药在治疗难治性患者（无反应者、合并HIV感染患者、失代偿性肝病患者和肝移植受者）中是否会发挥作用仍有待确定。
